These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 18075273

  • 41. Molecular targets for disrupting leukocyte trafficking during multiple sclerosis.
    McCandless EE, Klein RS.
    Expert Rev Mol Med; 2007 Jul 19; 9(20):1-19. PubMed ID: 17637110
    [Abstract] [Full Text] [Related]

  • 42. Molecular and immunogenic features of myelin lipids: incitants or modulators of multiple sclerosis?
    Podbielska M, Hogan EL.
    Mult Scler; 2009 Sep 19; 15(9):1011-29. PubMed ID: 19692432
    [Abstract] [Full Text] [Related]

  • 43. Genetic models for CNS inflammation.
    Owens T, Wekerle H, Antel J.
    Nat Med; 2001 Feb 19; 7(2):161-6. PubMed ID: 11175845
    [Abstract] [Full Text] [Related]

  • 44. Impact of myelin-specific antigen presenting B cells on T cell activation in multiple sclerosis.
    Harp CT, Lovett-Racke AE, Racke MK, Frohman EM, Monson NL.
    Clin Immunol; 2008 Sep 19; 128(3):382-91. PubMed ID: 18599355
    [Abstract] [Full Text] [Related]

  • 45. The role of CD8 suppressors versus destructors in autoimmune central nervous system inflammation.
    Zozulya AL, Wiendl H.
    Hum Immunol; 2008 Nov 19; 69(11):797-804. PubMed ID: 18723060
    [Abstract] [Full Text] [Related]

  • 46. Specific central nervous system recruitment of HLA-G(+) regulatory T cells in multiple sclerosis.
    Huang YH, Zozulya AL, Weidenfeller C, Metz I, Buck D, Toyka KV, Brück W, Wiendl H.
    Ann Neurol; 2009 Aug 19; 66(2):171-83. PubMed ID: 19705413
    [Abstract] [Full Text] [Related]

  • 47. Comparison of CNS and PNS myelin proteins in the pathology of myelin disorders.
    Quarles RH.
    J Neurol Sci; 2005 Feb 15; 228(2):187-9. PubMed ID: 15694201
    [No Abstract] [Full Text] [Related]

  • 48. Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy.
    Steinman L, Martin R, Bernard C, Conlon P, Oksenberg JR.
    Annu Rev Neurosci; 2002 Feb 15; 25():491-505. PubMed ID: 12052918
    [Abstract] [Full Text] [Related]

  • 49. Molecular "negativity" may underlie multiple sclerosis: role of the myelin basic protein family in the pathogenesis of MS.
    Musse AA, Harauz G.
    Int Rev Neurobiol; 2007 Feb 15; 79():149-72. PubMed ID: 17531841
    [Abstract] [Full Text] [Related]

  • 50. [The remyelination phenomenon in multiple sclerosis].
    Lubetzki C.
    Bull Acad Natl Med; 2003 Feb 15; 187(4):699-707; discussion 707-10. PubMed ID: 14556477
    [Abstract] [Full Text] [Related]

  • 51. Therapeutic antibodies in multiple sclerosis.
    Goebels N, Becher B.
    Neurodegener Dis; 2008 Feb 15; 5(1):5-7. PubMed ID: 18075268
    [No Abstract] [Full Text] [Related]

  • 52. Prostaglandins in pathogenesis and treatment of multiple sclerosis.
    Mirshafiey A, Jadidi-Niaragh F.
    Immunopharmacol Immunotoxicol; 2010 Dec 15; 32(4):543-54. PubMed ID: 20233088
    [Abstract] [Full Text] [Related]

  • 53. Therapeutic targeting of chemokine signaling in Multiple Sclerosis.
    Hamann I, Zipp F, Infante-Duarte C.
    J Neurol Sci; 2008 Nov 15; 274(1-2):31-8. PubMed ID: 18706659
    [Abstract] [Full Text] [Related]

  • 54. Modulation of immune response by head injury.
    Morganti-Kossmann MC, Satgunaseelan L, Bye N, Kossmann T.
    Injury; 2007 Dec 15; 38(12):1392-400. PubMed ID: 18048036
    [Abstract] [Full Text] [Related]

  • 55. [Gamma globulin therapy in multiple sclerosis. Theoretical considerations and initial clinical experiences with 7S immunoglobulins in MS therapy].
    Soukop W, Tschabitscher H.
    Wien Med Wochenschr; 1986 Sep 30; 136(18):477-80. PubMed ID: 2948324
    [Abstract] [Full Text] [Related]

  • 56. Notes on the pathogenesis of multiple sclerosis.
    Poser CM.
    Clin Neurosci; 1994 Sep 30; 2(3-4):258-65. PubMed ID: 7749896
    [Abstract] [Full Text] [Related]

  • 57. Regulatory effects of IFN-beta on production of osteopontin and IL-17 by CD4+ T Cells in MS.
    Chen M, Chen G, Nie H, Zhang X, Niu X, Zang YC, Skinner SM, Zhang JZ, Killian JM, Hong J.
    Eur J Immunol; 2009 Sep 30; 39(9):2525-36. PubMed ID: 19670379
    [Abstract] [Full Text] [Related]

  • 58. Diffusely abnormal white matter in chronic multiple sclerosis: imaging and histopathologic analysis.
    Seewann A, Vrenken H, van der Valk P, Blezer EL, Knol DL, Castelijns JA, Polman CH, Pouwels PJ, Barkhof F, Geurts JJ.
    Arch Neurol; 2009 May 30; 66(5):601-9. PubMed ID: 19433660
    [Abstract] [Full Text] [Related]

  • 59. Exploring the role of nerve growth factor in multiple sclerosis: implications in myelin repair.
    Acosta CM, Cortes C, MacPhee H, Namaka MP.
    CNS Neurol Disord Drug Targets; 2013 Dec 30; 12(8):1242-56. PubMed ID: 23844684
    [Abstract] [Full Text] [Related]

  • 60. Inflammatory disease: assault on the guardian.
    Ransohoff RM.
    Nature; 2007 Jul 26; 448(7152):421-2. PubMed ID: 17653181
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.